DOXORUBICINA ACCORD 2mg / ml perfusive solution concentrate medication leaflet

L01DB01 doxorubicin • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances

Doxorubicinum is a chemotherapy drug used for the treatment of various types of cancer, including breast cancer, leukemia, and lymphoma. It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division and growth.

The medication is administered intravenously, usually as part of a specific regimen, under the supervision of an oncologist. It is effective in reducing tumor size and slowing disease progression.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and, in rare cases, cardiac toxicity. Close monitoring is essential during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Doxorubicinum. This medication must be administered exclusively in controlled environments, such as hospitals.

General data about DOXORUBICINA ACCORD 2mg / ml

Substance: doxorubicin

Date of last drug list: 01-06-2025

Commercial code: W65789003

Concentration: 2mg / ml

Pharmaceutical form: perfusive solution concentrate

Quantity: 1

Product type: generic

Price: 314.64 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: ACCORD HEALTHCARE LIMITED - MAREA BRITANIE

Holder: ACCORD HEALTHCARE POLSKA SP. Z O.O. - POLONIA

Number: 10647/2018/05

Shelf life: 18 months-after packing for marketing;after the first opening of the bottle-it is used immediately

Concentrations available for doxorubicin

10mg, 2mg/ml, 50mg

Other substances similar to doxorubicin

Compensation lists for DOXORUBICINA ACCORD 2mg / ml ACCORD

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

314.64 RON

314.64 RON

0.00 RON